KMT2A and acute myeloid leukemia: This first-in-human study tested ziftomenib in patients with relapsed/refractory AML and demonstrated a manageable safety profile and preliminary clinical activity in heavily pretreated patients with KMT2A-r or NPM1-m AML, warranting further investigation of this agent as a monotherapy and in combination with rational therapeutic partners [137,138,139].